Bloomberg reporting on Sep 8-18, trading 19th
The Chinese e-commerce operator, which plans to sell shares on the New York Stock Exchange, may set its IPO value at $154 billion, or 22 percent below analyst valuations, in a move that could avoid repeating Facebook Inc. (FB)'s listing flop, according to the average estimate in a Bloomberg survey of five analysts last month. The poll respondents give Alibaba an average post-listing valuation of $198 billion.
Alibaba is expected to begin an eagerly awaited roadshow for what could be the largest initial public offering ever early during the week of September 8, and its shares could list as soon as September 18 or 19, according to a person familiar with the situation.
The marketing trip will kick off in Asia, the person said. The Chinese e-commerce company is expected to raise about $20 billion when it lists on the New York Stock Exchange, rivaling the Agricultural Bank of China's $22.1 billion IPO from July 2010, currently the largest on record. A price range for the shares is typically given just ahead of the start of the roadshow.
Above from CNBC - also says internal valuation increased to $140 billion from $133
So Sep 18-19 Thursday or Friday IF SEC review completed
BioCryst Pharmaceuticals also rose after it announced plans to initiate a study of its Ebola drug on primates. It’s received an additional $2.4 million in government funding for the test. Shares were up more than two percent to $13.50.
New funding for BCX4430 is for dosing study, one of key elements of Animal rule approval (look up Animal Rule FDA Emeregency) is understanding PK well enough to have good idea of dosing.
Govt looking for something, anything that works. August 27 FBO notice of sole soul award to UVA for approach to attacking Ebola proteins for multiple strains. $ from DTRA
(CNN) -- A highly anticipated test of an experimental Ebola vaccine will begin next week at the National Institutes of Health, amid mounting anxiety about the spread of the deadly virus in West Africa.
After an expedited review by the U.S. Food and Drug Administration, researchers were given the green light to begin what's called a human safety trial, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
It will be the first test of this type of Ebola vaccine in humans.
The experimental vaccine, developed by the pharmaceutical company GlaxoSmithKline and the NIAID, will first be given to three healthy human volunteers to see if they suffer any adverse effects. If deemed safe, it will then be given to another small group of volunteers, aged 18 to 50, to see if it produces a strong immune response to the virus. All will be monitored closely for side effects.
From NIH Ebola Marburg research page updated Aug 14
Ebola Therapeutics Research
NIAID is supporting a number of projects designed to develop Ebola treatments. For example, NIAID supported Mapp Biopharmaceutical, Inc., in its development of a monoclonal antibody “cocktail” called MB-2003, which prevents Ebolavirus infection in mice and non-human primates when administered as post-exposure prophylaxis within one to two days of Ebolavirus infection. Additionally, NIAID currently is funding development of an optimized anti-Ebola monoclonal antibody product, zMapp, which has superior efficacy compared to earlier cocktails. The zMapp, which is partially derived from MB-2003, is a cocktail of three antibodies against Ebola.
In addition, NIAID is funding BioCryst Pharmaceuticals to develop and test BCX4430, a novel nucleoside with broad spectrum antiviral activity including against Ebolavirus. To date, BCX4430 has shown efficacy in animal infection models for Ebola and Marburg viruses. A Phase I trial is expected to begin in late 2014 or early 2015. NIAID also is supporting other monoclonal antibody-based broadly-protective filovirus immunotherapeutics.
25 Aug 2014: Japan to name criteria before offering unapproved EVD drug. Japan could offer an unapproved drug under certain circumstances to help treat the deadly ebolavirus, Reuters said. "Medical professionals could make a request for T-705 in an emergency even before a decision by the World Health Organization (WHO)," Chief Cabinet Secretary Yoshihide Suga said. "In that case, we would like to respond under certain criteria." Tokyo will cooperate with the WHO and is ready to make an international contribution. Japan's Fujifilm Holdings Corp and US's MediVector are in talks with the US Food and Drug Administration to submit an application to expand the use of the influenza drug T-705, or favipiravir, as a treatment for EVD.
of Alibaba road show - may talk more about core business, cash disposition of Baba proceeds, user metrics for mobile and video streaming
From Forbes story
“In fact, 3 drugs have already been approved under the Animal Rule: Johnson & Johnson’s levofloxacin (Yersinia pestis), GlaxoSmithKline’s raxibacumab (Bacillus anthracis, inhaled) and Cangene’s heptavalent botulism antitoxin BAT (Clostridium botulinum toxin). You’ll notice all three of these drugs are intended for use as post-exposure therapies – the same, relatively easy, path as ZMapp
Biocryst's Aug 13 press release said NAIAD through NIH, but the CDC's Q& A on experimental Ebola therapies says the Defense Threat Reduction Agency? Is this an inconsistency or a sequential funding issues?
Two other companies, Tekmira and Biocryst Pharmaceuticals, receive funding from the Department of Defense's Defense Threat Reduction Agency and have therapeutic candidates for Ebola in early development. The Department of Defense is working with a company called Newlink to develop an Ebola vaccine candidate. BioCryst, with NIH support, is working to develop an antiviral drug to treat Ebola virus that is expected to begin Phase 1 testing later this year.
Buyout of Yahoo will not occur until after Baba IPO, because the first thing you need is for BABA to go liquid, have access to capital markets post IPO, with maybe $15 billion proceeds in bank, another $5 CashonHand,
and even if Yahoo goes up above $45, the tax savings from a YHOO buy putting Yahoo share of BABA back internally offset any high cost to buy. But cash, and IPO, is king first.
Science: WHO and US examining novel therapies to see which should be moved forward quickly.
In an opening salvo against the Ebola virus, six people have received a test drug called ZMapp, made by Mapp Pharmaceuticals of San Diego. But supplies of that compound are exhausted and making more will take months. So WHO and the U.S. Department of Health and Human Services have pulled together experts to pore over research on other candidate drugs and vaccines. The goal is to decide which products to put into rapid safety tests, says Bausch, who is among those advising WHO. In the best-case scenario, WHO officials say, some of these test drugs could reach the field later this year — after safety testing in human volunteers. All have so far been tested only in monkeys and other animals. While ZMapp uses antibodies, other approaches combine that strategy with other antiviral agents or use RNA interference to thwart the virus.
US Govt committee meeting on clinical trial and ethics for experimental Ebola drugs - end of August
WHO Committee followup meeting on experimental drugs for Ebola - uses, supplies, dispersal Sep 4-5
Phase I clinical trial for BCX 4430 initiated by EOY
What precedent is there for using untested drugs in special cases?
The FDA approved the use of an unapproved antiviral drug called peramivir during the 2009 H1N1 influenza epidemic. And individual patients are often provided with unapproved drugs under 'compassionate use' guidelines; a US Marine, for instance, was treated with two unapproved drugs in 2009 to treat a runaway infection with vaccinia virus after a routine vaccination against smallpox. Usually, however, the medicines given in these situations have been proved to be safe in healthy people: “It’s very uncommon to use a drug that hasn’t undergone safety testing in humans, in ill volunteers,” says Jesse Goodman, head of the Center on Medical Product Access, Safety and Stewardship (COMPASS) at Georgetown University Medical Center in Washington DC. That’s because it is difficult to tell the side effects of a medicine from the normal course of a disease, and because ill people might be more vulnerable to side effects from an experimental drug.
HHS Q&A says Biocryst Ebola to start Phase 1 in 2014.
Are there other companies developing experimental treatments or vaccines?
Two other companies, Tekmira and Biocryst Pharmaceuticals, receive funding from the Department of Defense’s Defense Threat Reduction Agency and have therapeutic candidates for Ebola in early development. The Department of Defense is working with a company called Newlink to develop an Ebola vaccine candidate. BioCryst , with NIH support, is working to develop an antiviral drug to treat Ebola virus that is expected to begin Phase 1 testing later this year.